(1) A consortium may be established under this section and apply for selection by the department under this chapter to conduct a drug development clinical trial with ibogaine and secure the FDA’s approval of ibogaine as a medication for the treatment of:(a) Opioid use disorder;(b) Co-occurring substance use disorder; and(c) Any other neurological or mental health condition for which ibogaine demonstrates efficacy.
(a) Opioid use disorder;
(b) Co-occurring substance use disorder; and
(c) Any other neurological or mental health condition for which ibogaine demonstrates efficacy.
(2) A consortium established under this section must include one or more of each of the following entities:(a) A drug developer, which shall be the same drug developer that is part of the lead consortium;(b) An institution of higher learning; and(c) A hospital.
(a) A drug developer, which shall be the same drug developer that is part of the lead consortium;
(b) An institution of higher learning; and
(c) A hospital.